The American Society of Hematology (ASH) announces the 2010 recipients of its Trainee Research Awards. Through this program, which is designed to encourage the pursuit of research and spark an interest in hematology, 43 medical students, undergraduates, and residents will each receive $4,000 to conduct research on blood and blood-related diseases. In addition, each award winner is provided with travel stipends to attend the ASH annual meeting, one of the largest medical meetings in the country…

France has named Dr. Harry L. Messmore of Loyola University Health System a Knight of the Legion of Honor in recognition of his valor during World War II. In December, 1944, Messmore was part of a combat team that captured several heavily armed German pillboxes in France. Messmore, 87, lives in Indian Head Park

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) announced the launch of Cresp®’ the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy. Darbepoetin alfa is a modified version of epoetin alfa (rHuEPO), which is engineered to have a longer half life, increasing (up to 3 times) the time it remains in the blood…

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) announced the launch of Cresp®’ the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy. Darbepoetin alfa is a modified version of epoetin alfa (rHuEPO), which is engineered to have a longer half life, increasing (up to 3 times) the time it remains in the blood…

The American Society of Hematology (ASH) has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released in Blood, ASH’s premier scientific journal, in the article titled “Enhancing Research in Regenerative Medicine…

The American Society of Hematology (ASH) has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released in Blood, ASH’s premier scientific journal, in the article titled “Enhancing Research in Regenerative Medicine…

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line by The Lancet. Dr Ian Roberts, Professor of Epidemiology at the London School of Hygiene and Tropical Medicine (LSHTM), UK, revealed that results from a trial show that early administration of tranexamic acid (TXA) to patients with recent, severe bleeding injuries saves lives, with no evidence of adverse effects from unwanted clotting…

ICU Medical, Inc. (Nasdaq: ICUI), a worldwide leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in vascular therapy applications, confirmed that it has received FDA 510-k clearance for the Neutron™ Neutral-Pressure Needleless Connector…

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (STO: SOBI) announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies’ long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies…

HemoBioTech (Pink Sheets:HMBT) announced the issuance of a new patent US 7,759,306 B2, “Methods of Treating Acute Blood Loss.” HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The new patent involves HemoTech which induces the production of new red blood cells in the body. Uses for HemoTech could involve the treatment of acute blood loss and anemia in trauma, surgery, cancer, kidney disease and heart disease. The market for treatment of acute anemia is over $2 billion…